| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
EP ( EC50 = 10 nM )
CJ-042794 selectively targets the prostaglandin E receptor subtype 4 (EP4), a Gs-coupled receptor that mediates the effects of prostaglandin E2 (PGE2). By blocking EP4, the compound inhibits PGE2-evoked intracellular cAMP elevation. It has a mean pKi of 8.5 and an IC50 of 10 nM for the human EP4 receptor. The compound shows no meaningful binding to EP1 or EP3 and is >200-fold selective for EP4 over EP1, EP2, and EP3. |
|---|---|
| ln Vitro |
CJ-042794 (CJ-042794, 0.3-5000 nM; 10 min; hEP4/HEK293 cells) shows concentration-dependent inhibition of the PGE2-induced elevation of cAMP with a pIC50 value of 7.5[1].
CJ-042794 (3-3000 nM; 24 h) CJ-042794 reverses the inhibitory effects of PGE2 (10 nM) on the LPS-induced production of TNFα in human whole blood (HWB), with a pIC50 value of 6.4 in a concentration-dependent manner[1]. CJ-042794 is a potent antagonist of the EP4 receptor with an IC50 of 10 nM. It is >200-fold selective for EP4 over EP1, EP2, and EP3. The compound blocks PGE2-evoked intracellular cAMP elevation downstream of the Gs-coupled EP4 receptor. It demonstrates no meaningful binding to EP1 or EP3 receptors. |
| ln Vivo |
CJ-042794 (CJ-042794; 0.3-3 mg/kg; i.d.; once) inhibits AE1-329'sHCO3stimulatory action in the duodenum[1].
CJ-042794 (30 and 50 mg/kg; p.o.; once) has no gastric ulcerogenic response and does not harm the gastric mucosa of normal rats in response to cold-restraint stress[1]. CJ-042794 (30 and 50 mg/kg; p.o.; once) does not harm helper arthritis rats' stomachs or small intestines[1]. CJ-042794 (3-45 mg/kg; p.o.; twice daily for 14 d; Sprague-Dawley rats) promotes spontaneous healing of gastric ulcers[1]. The repeated administration of CJ-042794 (10 mg/kg; p.o.; daily, for 7 d) inhibits the healing process of chronic gastric ulcers by downregulating the expression of vascular endothelial growth factor in the ulcerated mucosa[1]. CJ-042794 is orally active and has been studied for its potential in treating chronic inflammatory pain. As a selective EP4 antagonist, it blocks the inflammatory effects of PGE2 mediated through the EP4 receptor. In vivo efficacy has been demonstrated in preclinical models of pain and inflammation. The compound's oral bioavailability supports its development as a therapeutic agent. |
| Enzyme Assay |
In vitro assays for CJ-042794 involve measuring the displacement of [3H]-PGE2 from the human EP4 receptor. Membranes from cells expressing recombinant EP4 are incubated with [3H]-PGE2 in the presence of varying concentrations of CJ-042794. Bound radioactivity is measured by scintillation counting, and pKi values are calculated from competition binding curves. Selectivity is assessed by testing the compound against EP1, EP2, and EP3 receptors.
|
| Cell Assay |
Cellular assays for CJ-042794 are performed using cells expressing recombinant EP4 receptors (e.g., CHO or HEK293 cells). Cells are treated with PGE2 in the presence or absence of CJ-042794, and intracellular cAMP levels are measured using a cAMP assay kit (e.g., HTRF or ELISA). The compound's ability to block PGE2-induced cAMP elevation is assessed, and IC50 values are calculated.
|
| Animal Protocol |
Male Sprague-Dawley rats (200-230 g)
0.3, 1, and 3 mg/kg intradermal injection; once In vivo animal studies with CJ-042794 are conducted in rodent models of inflammatory pain, such as the carrageenan-induced paw edema model or the complete Freund's adjuvant (CFA)-induced arthritis model. CJ-042794 is administered orally at various doses (typically 1-30 mg/kg). Pain threshold, paw swelling, and inflammatory cytokine levels are measured. The compound's efficacy in reducing pain and inflammation is assessed. |
| ADME/Pharmacokinetics |
CJ-042794 is orally active and has favorable pharmacokinetic properties. Its molecular weight is approximately 413.85 g/mol. The compound is metabolized in the liver, and its half-life supports once- or twice-daily dosing. For research use, it is typically dissolved in DMSO for in vitro studies and formulated in suitable vehicles for oral administration.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for CJ-042794 are limited. In preclinical studies, no significant adverse effects have been reported at therapeutic doses. The compound's selectivity for EP4 minimizes off-target effects. However, comprehensive toxicity studies have not been published. The compound should be handled with standard laboratory safety precautions.
|
| References |
|
| Additional Infomation |
Benzoic acid, 4-[(1s)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]- is an aromatic ether.
CJ-042794 is a research compound developed as a selective EP4 antagonist for the treatment of chronic inflammatory pain. It has been studied in preclinical models and has shown promise as a potential therapeutic agent. The compound is not approved for clinical use and is intended for laboratory research only. |
| Molecular Formula |
C22H17CLFNO4
|
|---|---|
| Molecular Weight |
413.8261
|
| Exact Mass |
413.083
|
| Elemental Analysis |
C, 63.85; H, 4.14; Cl, 8.57; F, 4.59; N, 3.38; O, 15.46
|
| CAS # |
847728-01-2
|
| PubChem CID |
11524454
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
572.7±50.0 °C at 760 mmHg
|
| Flash Point |
300.2±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.616
|
| LogP |
5.91
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C1C=CC(F)=CC=1)C1=CC=C(Cl)C=C1C(=O)N[C@H](C1C=CC(C(=O)O)=CC=1)C
|
| InChi Key |
MWBNCZHVEXULBD-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C22H17ClFNO4/c1-13(14-2-4-15(5-3-14)22(27)28)25-21(26)19-12-16(23)6-11-20(19)29-18-9-7-17(24)8-10-18/h2-13H,1H3,(H,25,26)(H,27,28)/t13-/m0/s1
|
| Chemical Name |
4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid
|
| Synonyms |
CJ-042794; CJ-042794; CJ-042794; RQ-00015986; RQ-15986
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 28 mg/mL (~67.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.04 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4165 mL | 12.0823 mL | 24.1645 mL | |
| 5 mM | 0.4833 mL | 2.4165 mL | 4.8329 mL | |
| 10 mM | 0.2416 mL | 1.2082 mL | 2.4165 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA